Wegovy

Patient

Questions for this perspective

13 drafted questions in this packet. A perspective-specific question set.

1. How does Wegovy work?

Established. Wegovy acts on the GLP-1 receptor, a signal receiver linked to hunger. It helps people eat less. It also changes signals from the pancreas that help control blood sugar. Food leaves the stomach more slowly, but that is not the whole reason for weight loss. The drug does not melt fat. Pills and shots share an active drug, yet their uses and instructions differ. Check which one your care team means.

Sources: L §§1,12.

2. How much weight did people lose, and how fast?

Established. In STEP 1, adults without diabetes lost about 15% of starting weight over 68 weeks with the shot. The placebo group lost about 2%. Both groups had support with food and activity. Half of those on the drug lost at least 15%. Those are study results, not a promise for you. Tell the care team about symptoms and how you feel as well as any change on the scale.

Sources: STEP1.

3. Is the pill as strong as the injection?

Established. The pill and shot contain the same active drug, but different amounts get into blood. The pill uses a special ingredient to help it cross the stomach lining. Its effect is not judged by matching milligram numbers. In a pill study, average weight loss was 13.6% over 64 weeks, versus 2.2% with placebo. That was not a direct test against the shot. Ask which product fits your care plan.

Sources: L §12.3; OASIS.

4. What is Wegovy approved for?

Established. Both forms have uses for weight control in eligible adults and for lowering certain heart risks in adults with known heart disease and overweight or obesity. The shot also has an obesity use from age 12. A specific liver use is for adults and belongs to the shot. The higher-dose shot is not for every use. The care team must check your health history and the exact product before treatment.

Sources: L §§1,2,8.4.

5. Does it burn only fat or just slow the stomach?

Established. The drug helps reduce food intake. Slower stomach emptying is one effect, but it does not explain all the weight change. The label says more fat mass than lean mass is lost, not that all the loss is fat. How you feel, eat and function matters too. Keep the food and activity plan agreed with your care team, and tell them about weakness, poor intake or symptoms that last.

Sources: L §12.2; Appetite; DXA.

6. What does the heart benefit mean?

Established. SELECT studied people with known heart disease and overweight or obesity, without diabetes. It followed them for about three years and four months. About 6 to 7 out of 100 taking the shot had a heart attack, stroke or heart-related death. About 8 out of 100 taking placebo did. That cannot predict your result. The label also covers eligible adults using pills. SELECT itself tested the shot, not the pill.

Sources: SELECT; L §1.

7. Does the liver use cover any fatty liver?

Established. No. The liver use is for adults with a disease called MASH and certain stages of scarring, F2–F3, without cirrhosis. It belongs to the shot, not the pill. A trial found better results on liver samples. That does not yet prove fewer cases of liver failure or death. The care team must check the diagnosis and stage. A change in weight or a liver blood test alone is not enough.

Sources: L §1; ESSENCE.

8. Which side effects are common?

Established. Nausea, vomiting, diarrhea, constipation and belly pain are common. Headache and tiredness can occur too. Rates differ across products and studies. Tell the care team if symptoms are bad or last. Let them know if you cannot keep fluids down. The drug is not recommended with severe gastroparesis. That means the stomach empties very slowly. Tell the clinician if you have it. Do not assume all stomach trouble is routine.

Sources: L §§5.6,6.1.

9. Which symptoms need urgent help?

Established. Severe belly pain that lasts needs medical advice right away. Trouble breathing or swelling of the face, tongue or throat needs emergency help. Promptly report new sight changes, lasting vomiting or diarrhea, or a racing heart at rest. Upper belly pain with fever or yellow skin also needs a call. Do not wait for a routine visit to report these symptoms. This page cannot tell you their cause or rule out harm.

Sources: L §5; Medication Guide.

10. What does the boxed thyroid warning mean?

Established. Semaglutide caused thyroid C-cell tumors in rodents. Whether it causes them in people is unknown. The label rules out use if you or a family member has had medullary thyroid cancer, or if you have MEN2. A prior serious allergy to the drug or its ingredients also rules it out. Tell the prescriber about that history. A neck lump, lasting hoarseness or trouble swallowing needs assessment.

Sources: L boxed warning; §§4,5.1,5.7.

11. What about other drugs or an upcoming procedure?

Established. Using Wegovy with another semaglutide product or another GLP-1 drug is not recommended. Insulin or a sulfonylurea can raise low-sugar risk. Give the care team your full drug list. Tell the anesthesia team before surgery or deep sedation, since food or liquid entering the lungs has been reported. Let that team make the procedure plan. Never share a FlexTouch pen, even with a new needle. Do not plan a switch yourself.

Sources: L §§1,5,7.

12. What about pregnancy or breastfeeding?

Established. Talk to the prescriber promptly if you are pregnant or plan to be. The drug stays in the body for weeks and may harm a fetus. The right plan depends in part on why you take it, especially with the liver use. The labels include a two-month planned-pregnancy interval, with wording that needs careful product review. Breastfeeding is not recommended with pills. The shot has different guidance to discuss with the clinician.

Sources: L §§8.1–8.3; [VERIFY: reconcile label copies before clinical release].

13. Where can I check the right product and access options?

Established. Use the official product site and the label for the exact box, then check with your pharmacist or care team. A prescription and a clinical assessment are required. An online offer does not prove you qualify or that a pharmacy has stock. Prices and terms can change. Ask which pack, date and eligibility rules apply. Do not swap a pill, standard shot or HD because a price looks better.

Sources: L §§1,2; HD; CMS; [VERIFY: current individual access].

Caregiver

Questions for this perspective

8 drafted questions in this packet. A perspective-specific question set.

1. How can I help without judging the person’s weight?

Established. Ask what support the person wants. They may want help reading a box, keeping notes or joining a visit. Follow the care team’s food and activity plan without treating weight as a test of effort or character. Note symptoms and questions as well as weight, if tracking is part of the plan. The prescriber makes treatment changes. Your role is to help the person share what is happening and get clear answers.

Sources: L §§1,17; editorial care-support guidance.

2. Which symptoms need urgent help or a call today?

Established. Severe belly pain that lasts needs urgent medical advice. Trouble breathing or swelling of the face, tongue or throat needs emergency help. Promptly report new sight changes, lasting vomiting or diarrhea, or a racing heart at rest. Upper belly pain with fever or yellow skin also needs a call. Note when the symptoms began and which product is used. Do not assume a serious symptom is just expected nausea.

Sources: L §§5,17; Medication Guide.

3. Was there a suicide warning, and is it still there?

Established. The inspected labels no longer include that warning. FDA asked for removal in January 2026. Its review found no increased risk with these drugs. The label copies record different removal months, which need a date check. Mood changes still deserve care and a prompt talk with the team. If someone is in immediate danger, seek emergency help. A removed drug warning is not a reason to ignore distress.

Sources: Warning; L/FDA/manufacturer recent changes; [VERIFY: removal chronology].

4. What should I do if a weekly dose is missed?

Established. Help check the date of the last dose and the next planned dose. Wegovy’s rule depends on how close the next dose is, and missing more than one can require a new start plan. Ask the pharmacist or prescriber to check the timing if it is unclear. Do not use the rule for another brand or guess a catch-up dose. Keep the team’s instructions with the medicine so both of you can find them.

Sources: L §2.4.

5. What should I record between visits?

Established. With the person’s agreement, record symptoms, trouble eating or drinking, and a racing heart at rest. Note new sight changes and low-sugar episodes if those are part of the care plan. Keep an accurate drug list and bring the box if the product has changed. These notes help the team assess benefit and side effects together. They are not a reason to change a dose or judge success from weight alone.

Sources: L §§5,17.

6. How do I check that we have the right product?

Established. Read the box together: is it a pill, a standard shot or HD? The instructions and approved uses differ. Pills are for adults; the teen obesity and liver uses belong to injection. The higher-dose shot is not for every use. Ask the pharmacist about an unfamiliar box or device before it is used. A FlexTouch pen must never be shared, even if someone puts on a new needle.

Sources: L §§1,2,3,5.11.

7. What family or allergy history should we mention?

Established. Tell the prescriber about medullary thyroid cancer in the person or their family, or MEN2. Those histories rule out use under the label. A prior serious allergy to the drug or its ingredients also rules it out. The boxed warning comes from thyroid tumors in rodents; the human risk is unknown. A neck lump, lasting hoarseness or trouble swallowing needs assessment. Other thyroid problems need their own discussion, not a guess.

Sources: L boxed warning; §§4,5.1,5.7.

8. Can less hunger mean all weight lost is fat?

Established. No. The label says fat loss was greater than lean-mass loss, not that all the lost weight was fat. A small study of body composition found changes in both. A scale alone cannot show muscle strength or health. Help the person follow their agreed food and activity plan and report concerns about weakness or poor intake. Avoid praising a lower number when the person feels unwell or cannot eat enough.

Sources: L §12.2; DXA; editorial support guidance.

Pharmacist

Questions for this perspective

8 drafted questions in this packet. A perspective-specific question set.

1. Can Wegovy be added to an existing Ozempic prescription?

Established. The Wegovy label does not recommend concurrent use with another semaglutide-containing product or any other GLP-1 receptor agonist. The names may suggest different treatment goals, but that does not make the combination appropriate. Reconcile every injectable and oral product, including recent changes, before dispensing. If the intention is a transition, clarify the prescriber’s exact plan rather than allow overlapping products or infer a conversion from their printed milligram strengths.

Sources: L §1; §§2.2–2.5.

2. Which tablet instructions are essential?

Established. The label specifies a morning dose on an empty stomach with water only, up to four ounces, followed by at least 30 minutes before food, beverages or other oral medicines. Tablets are swallowed whole, not split, crushed, chewed or dissolved. Estimated oral bioavailability is about 1–2%, making administration conditions relevant. Use teach-back to check the patient’s actual routine, particularly when other morning medicines compete for the same fasting interval.

Sources: L §§2.1,12.3.

3. What does 44 versus 68 nmol/L actually compare?

Established. Those average steady-state concentrations describe oral 25 mg and injected 2.4 mg semaglutide in T2D datasets, respectively. The label separately gives approximately 77 versus 75 nmol/L in overweight/obesity without T2D, with greater oral variability. Do not use one pair as a universal pill-versus-injection comparison. These are exposure summaries with population qualifications, not a conversion formula or a head-to-head demonstration of equal clinical response for every person.

Sources: L §§8.6,12.3.

4. What is the label’s framework for changing route?

Established. Section 2.5 describes specific transitions between maintenance oral 25 mg and injected 2.4 mg for adult weight or cardiovascular use, with different timing by direction and additional tolerability considerations. That framework is narrower than free interchange among all strengths, HD, pediatric use or MASH treatment. Confirm the indication, current route, tolerated dose and prescriber order before applying it. A public explanation should point to the table without turning it into personal switching advice.

Sources: L §2.5.

5. How do missed-dose rules differ from Ozempic?

Established. Wegovy’s injection rule depends on time until the next scheduled dose: more than two days allows the missed dose; less than two days means skip it. Repeated missed injections require a clinician-directed restart using the applicable label. A missed tablet is skipped, with the next taken the following day. These rules must not be replaced with Ozempic’s five-day rule. Clarify exact timing or boundary uncertainty instead of inventing a rule for an individual.

Sources: L §2.4.

6. Which safety histories and interactions belong in reconciliation?

Established. Check the boxed rodent C-cell tumor warning and MTC/MEN2 or serious-hypersensitivity contraindications. Identify insulin or sulfonylureas, which raise hypoglycemia risk, and oral medicines needing close monitoring. Oral semaglutide increased levothyroxine exposure in the labeled study; that is not an automatic dose-reduction percentage. Severe gastroparesis is separately not recommended. Preserve these categories and exact product instructions when coordinating questions with the prescriber rather than treating all cautions as equivalent contraindications.

Sources: L boxed warning; §§4,5,7,12.3.

7. Why does device-specific counseling matter?

Established. The label includes single-dose pens, single-dose syringes and a FlexTouch presentation, alongside tablets. Training should match the dispensed package, and a presentation change requires renewed instruction. FlexTouch must never be shared, even with a changed needle. Storage and in-use allowances also depend on the product. Confirm the actual package’s Instructions for Use rather than distribute one generic semaglutide device card or assume that all listed presentations are locally stocked.

Sources: L §§2.1,3,5.11,16.2.

8. How should price and coverage questions be framed?

Established. Distinguish list price, a manufacturer offer, an insurance benefit and the CMS Bridge demonstration. The manufacturer’s April 2026 introductory $199 offer had a June deadline, so it should not be advertised as a current October price. CMS describes a $50 copay for eligible Bridge participants, with authorization requirements. Verify the exact product, current terms and patient eligibility separately; an educational page cannot establish stock, coverage or a final transaction price.

Sources: HD; CMS; [VERIFY: current terms and eligibility].

Clinician

Questions for this perspective

8 drafted questions in this packet. A perspective-specific question set.

1. What is the SELECT NNT for MACE?

Established. SELECT reported MACE in 6.5% with injected semaglutide and 8.0% with placebo during mean 39.8-month follow-up. The rounded absolute difference is 1.5 percentage points; its reciprocal is 66.67, rounded up to approximate NNT 67. This crude estimate differs from a survival-model NNT and is tied to the trial population. HR was 0.80 with 95% CI 0.72–0.90; it does not imply equal benefit for every composite component.

Sources: SELECT; L §14.1.

2. Does the MASH indication cover F1 fibrosis or cirrhosis?

Established. The label specifies adults with noncirrhotic MASH and moderate-to-advanced fibrosis corresponding to F2–F3. It does not make Wegovy a general fatty-liver, F1 or cirrhosis treatment. ESSENCE’s interim histology results supported accelerated approval, with confirmatory clinical benefit still required. Confirm the diagnosis, fibrosis stage, formulation and treatment goal before discussing the indication; neither a liver-enzyme improvement nor a weight response alone establishes that a patient meets this labeled population.

Sources: L §1; ESSENCE.

3. How should STEP UP’s 18.7% and 20.7% results be used?

Established. The main STEP UP abstract reports treatment-policy weight change of −18.7% at 7.2 mg versus −15.6% at 2.4 mg and −3.9% with placebo over 72 weeks. The 20.7% headline uses a different estimand reflecting continued treatment without other weight therapies. State which question each estimate answers before comparing them. Mixing an on-treatment estimate with another trial’s treatment-policy result exaggerates comparability and can mislead expectations in routine care.

Sources: UP; HD.

4. What does OASIS 4 establish for tablets?

Established. OASIS 4 randomized 307 adults without diabetes to oral semaglutide 25 mg or placebo with lifestyle intervention. At week 64, estimated weight change was −13.6% versus −2.2%; gastrointestinal adverse events occurred in 74.0% versus 42.2%. It was not a head-to-head injection trial and did not establish pediatric or MASH efficacy. The label also states that tablet weight reduction has not been studied in adults with T2D and overweight or obesity.

Sources: OASIS; L §§8.6,14.2.

5. How should lean-mass findings enter counseling?

Established. The exploratory STEP 1 DXA abstract included 140 participants. Semaglutide-group fat mass fell 19.3% and lean body mass 9.7%, while lean mass as a proportion of total weight increased. Those statements use different denominators and are compatible. DXA lean mass is not a direct measure of skeletal-muscle function or a diagnosis of sarcopenia. Discuss body composition and functional concerns without claiming that every kilogram lost is fat or that a higher lean proportion proves muscle gain.

Sources: DXA; L §12.2.

6. Which risks can change product selection or follow-up?

Established. MTC/MEN2 and serious hypersensitivity contraindications, with the boxed rodent thyroid warning, remain essential. Assess severe gastroparesis, persistent GI symptoms with volume depletion, pancreatitis or gallbladder symptoms, resting pulse, retinopathy history and hypoglycemia-prone combinations. These factors are not interchangeable label categories. The outcome benefit does not settle an individual benefit-risk judgment, and a higher injection dose is not automatically appropriate for every indication or for pediatric treatment.

Sources: L boxed warning; §§1,2,4,5.

7. How should pregnancy language be handled across label copies?

Uncertain. The inspected DailyMed and FDA/manufacturer artifacts differ in some pregnancy wording despite sharing a June 2026 revision label. FDA/manufacturer text separates CV/weight use from individualized MASH benefit-risk assessment; planned-pregnancy advice also has indication-specific language. The draft records the discrepancy and directs early prescriber discussion, rather than issuing a universal personal stop plan. Reconcile the current authoritative product instructions and indication before clinical release or counseling from a simplified summary.

Sources: L §§8.1–8.3; FDA/manufacturer cross-checks in 02; [VERIFY: label reconciliation].

8. Which guideline statement can this draft substantiate?

Established. The AGA 2022 guideline abstract supports adding pharmacotherapy to lifestyle intervention for eligible adults with inadequate response and suggests semaglutide 2.4 mg with moderate-certainty evidence. That document predates tablet, HD and MASH expansions. The ADA 2026 citation has been identified, but its exact recommendation wording remains to be checked. Keep a dated guideline statement separate from the current label and avoid inventing recommendation grades for newer formulations or indications.

Sources: AGA; ADA8; [VERIFY: full current ADA and hepatology guidance].

Nurse

Questions for this perspective

8 drafted questions in this packet. A perspective-specific question set.

1. What should be checked before teaching administration?

Established. Identify the exact tablet or injection presentation and the prescribed indication before teaching. The label calls for presentation-specific training and renewed instruction when the device changes. Weekly injection is given on the same day, with or without meals, using rotated abdomen, thigh or upper-arm sites. Daily tablets have a separate morning fasting routine. Use the actual package and teach-back; familiarity with a different semaglutide product does not establish correct technique here.

Sources: L §§2.1,3.

2. Which pulse changes need reporting?

Established. The label reports mean resting pulse increases of 1–4 beats per minute versus placebo in adult injection weight trials. That average is not a threshold below which symptoms can be ignored. Monitor pulse according to the clinical plan and ask about palpitations or a racing heartbeat at rest, which the label says to report. A sustained increase requires clinician assessment and label-directed management; do not independently change treatment from a classroom average.

Sources: L §5.9.

3. What if a weekly dose has been missed?

Established. Confirm when the last dose was taken and when the next is scheduled. The label distinguishes more than two days until the next dose from less than two days; repeated missed injections require a restart plan. Do not apply Ozempic’s different missed-dose rule or guess what to do at an unclear timing boundary. Route uncertainty to the pharmacist or prescriber and document the instructions actually given to the patient.

Sources: L §2.4.

4. What GI findings suggest more than routine tolerance problems?

Established. Persistent vomiting or diarrhea, inability to maintain fluids and signs of volume depletion warrant assessment because kidney injury has been reported. Severe persistent abdominal pain, sometimes radiating to the back, needs urgent evaluation for possible pancreatitis. Upper abdominal pain with fever or jaundice also needs attention. Record symptom timing and severity without diagnosing from the animation. Weight reduction or expected nausea does not make these warning symptoms harmless.

Sources: L §§5.2,5.3,5.5,5.6; Medication Guide.

5. What belongs in hypoglycemia and vision teach-back?

Established. For patients with diabetes, confirm the prescribed glucose-monitoring plan and whether insulin or a sulfonylurea is used. Ask them to explain the low-glucose action plan and whom to contact for recurrent episodes. Also ask about retinopathy history and new vision changes. Rapid glucose improvement can coexist with eye complications, so a favorable glucose trend does not remove the need for reporting symptoms or following the clinician’s eye-monitoring plan.

Sources: L §§2.1,5.4,5.8.

6. How should the thyroid warning be explained during assessment?

Established. Explain that semaglutide caused C-cell tumors in rodents and that human relevance is unknown. Check personal or family medullary thyroid cancer, MEN2 and prior serious allergy to the product, which are contraindication histories. Report a new neck lump, persistent hoarseness or trouble swallowing for assessment. Keep this separate from the common GI-effects discussion so the boxed warning is neither lost nor expanded into a false claim that every thyroid condition rules out treatment.

Sources: L boxed warning; §§4,5.1,5.7.

7. What should be documented before anesthesia or deep sedation?

Established. Document semaglutide use, route, recent administration and relevant GI symptoms, and make sure the procedural team knows. Aspiration has been reported despite usual fasting, but the label does not establish one universal hold interval that prevents it. Confirm the plan made by the anesthesia and prescribing teams instead of replacing it with a generic rule. Teaching should help the patient disclose the medicine and follow the agreed instructions.

Sources: L §5.10.

8. How does adolescent teaching differ?

Established. The injection’s obesity indication includes ages 12 and older; tablets and the 7.2 mg regimen do not have established pediatric safety and effectiveness. STEP TEENS assessed BMI change, which differs from adult percentage body-weight change. Involve the adolescent respectfully and use appropriate caregiver support without treating weight as a judgment of effort or character. Confirm the actual presentation, glucose risks where relevant, symptom reporting and clinician-led follow-up rather than borrow an adult tablet routine.

Sources: L §§1,8.4; TEENS; editorial communication guidance.

Student

Questions for this perspective

8 drafted questions in this packet. A perspective-specific question set.

1. Why does gastric slowing not fully explain weight loss?

Established. In a randomized study of 72 adults with obesity, semaglutide 2.4 mg reduced ad-libitum meal intake by 35% at week 20. The indirect gastric-emptying test did not show delay at that time. Those observations support separating appetite and food intake from one stomach-emptying measure. They do not prove that gastric effects never occur, especially earlier in treatment, or that the entire human weight-response pathway has been mapped.

Sources: Appetite; L §§12.1–12.2.

2. What is the receptor-to-signal sequence?

Established. Semaglutide activates the GLP-1 receptor, a class B G-protein-coupled receptor. Structural work captures a receptor–Gs complex, and cellular assays study cAMP signaling. Connect those experimental findings to appetite-related brain pathways and pancreatic hormone responses, but avoid drawing every downstream step as directly established in humans. A molecular starting point explains biological plausibility; human trials are still needed to measure weight change, cardiovascular events or liver-biopsy responses.

Sources: Structure; L §12.

3. What do POMC/CART and NPY/AgRP results actually show?

Established. The cited Secher study concerns liraglutide in rodents and GLP-1 responses in murine brain slices. It reports direct stimulation of POMC/CART neurons and indirect inhibition of NPY/AgRP signaling through GABA-related mechanisms. These are useful circuit findings, but they are not a complete human semaglutide map. Keep the studied ligand, species and method attached to the claim instead of relabeling every GLP-1-class experiment as direct evidence for Wegovy.

Sources: Secher; Neural.

4. Why is hypoglycemia still possible?

Established. Semaglutide’s pancreatic effects depend on glucose, but the label states that it can lower blood glucose and cause hypoglycemia. Insulin or sulfonylureas increase the risk further. Learn the mechanism and warning together: glucose dependence describes part of the physiology, not an absolute clinical guarantee. Patients with diabetes need the monitoring and action plan supplied by their care team, and the combination may require clinician-led adjustment of another medicine.

Sources: L §§2.1,5.4,7.1,12.2.

5. Why should gallstones not be explained only by rapid weight loss?

Established. Rapid or substantial weight loss can increase gallstone risk, but the Wegovy label reports more acute gallbladder disease than placebo even after accounting for weight loss. Therefore the phrase rapid loss causes all gallstones is too simple. Use the label to describe the association and symptoms needing assessment, then mark the complete causal pathway as unresolved rather than infer a single mechanism from the fact that body weight fell.

Sources: L §5.3.

6. How do body-weight percentage and BMI percentage differ?

Established. STEP 1 reported percentage change in body weight in adults, whereas STEP TEENS used percentage change in BMI as its primary endpoint. BMI includes height, which matters when studying growing adolescents. The reported −14.9% adult weight and −16.1% adolescent BMI results therefore cannot be treated as the same measurement or a cross-age ranking. State the endpoint, population and time horizon before comparing a number with another trial.

Sources: STEP1; TEENS.

7. What is accelerated approval based on histology?

Established. For Wegovy’s MASH indication, improved liver-biopsy endpoints supported accelerated approval in adults with noncirrhotic F2–F3 disease. ESSENCE’s interim results measured MASH resolution and fibrosis improvement under specified paired conditions. They did not yet establish fewer liver-failure events or deaths. The label requires confirmation of clinical benefit. Learn the distinction between a tissue endpoint, a clinical outcome and the regulatory pathway rather than treating the approval as proof of every long-term consequence.

Sources: ESSENCE; L §1.

8. How does semaglutide differ mechanistically from tirzepatide?

Established. Semaglutide is a GLP-1 receptor agonist, while tirzepatide activates both GIP and GLP-1 receptors according to its current label. That target distinction is a starting point for comparison, not proof that two receptors always produce a better clinical result. Use an appropriate head-to-head trial before discussing superiority. Formulation, dose, population and endpoint can all matter more than the number of named receptors alone when interpreting a clinical comparison.

Sources: L §12.1; Zepbound label §12.1; [VERIFY: comparator clinical evidence before superiority claims].

Scientist

Questions for this perspective

8 drafted questions in this packet. A perspective-specific question set.

1. Which human experiment measures the appetite effect directly?

Established. Friedrichsen’s randomized study measured appetite-related outcomes and ad-libitum energy intake in 72 adults with obesity after a regimen reaching 2.4 mg weekly. At week 20, meal intake was 35% lower than with placebo. This directly measures a human behavioral endpoint under study conditions, but it does not establish a regional neural mediator or every person’s long-term intake. Keep dose, duration, population and test meal attached to the number.

Sources: Appetite.

2. How does semaglutide reach appetite-related brain regions?

Uncertain. Gabery’s rodent work describes access and responses in selected regions, including areas associated with circumventricular access, rather than unrestricted brain penetration. That evidence should not be translated into a definitive whole-human-brain distribution map or the blanket claim that no relevant barrier crossing ever occurs. A clinical appetite effect does not establish the route taken by every molecule. Distinguish animal localization, receptor-dependent access and human functional outcomes when formulating the next experiment.

Sources: Neural; L §12.1.

3. Does SELECT identify a weight-independent cardiovascular pathway?

Uncertain. SELECT demonstrates a randomized treatment effect on MACE in its studied population, but the primary result does not partition the effect into weight-dependent and weight-independent components. Mediation analyses need their own methods, assumptions and uncertainty assessment. The label states that the exact cardiovascular protective mechanism is not established. Do not infer a direct vascular mechanism merely because events fell, or dismiss mediation questions because the total clinical effect is clear.

Sources: SELECT; L §12.1.

4. What does ESSENCE leave unresolved mechanistically?

Uncertain. ESSENCE’s interim findings establish changes in paired histologic endpoints in F2–F3 MASH. They do not isolate direct hepatic effects from weight-mediated or other systemic pathways, and they do not yet establish the clinical-outcome consequences of those tissue changes. The label explicitly describes the precise human mechanism as incompletely understood. Proposed liver-cell arrows in an animation should therefore be labeled hypotheses or omitted unless the specific experimental evidence supports them.

Sources: ESSENCE; L §12.1.

5. How should oral exposure variability be interpreted?

Established. The label reports broader average-concentration ranges with oral 25 mg than injected 2.4 mg, and separately presents T2D and non-T2D datasets. The familiar 44 versus 68 nmol/L means belong to T2D; non-T2D means are approximately 77 versus 75. These data describe exposure distributions under stated conditions, not a randomized demonstration of identical clinical response. A formulation study should distinguish between-person variability, administration conditions and the population used for each comparison.

Sources: L §§8.6,12.3.

6. What can the DXA subset establish about lean tissue?

Established. The exploratory STEP 1 DXA abstract measured body composition in 140 participants, with 95 assigned semaglutide and 45 placebo. Semaglutide-group lean mass decreased while its proportion of total mass increased because other compartments changed too. The finding does not directly measure muscle quality, strength or physical performance. Subset selection, scanner methods and the abstract format limit inference; a functional or sarcopenia claim needs additional endpoints and appropriate definitions.

Sources: DXA.

7. Why distinguish estimands in STEP UP?

Established. The main treatment-policy estimate addresses effects regardless of discontinuation or additional weight therapies, whereas the larger efficacy estimate addresses a different hypothetical treatment scenario. Both can be informative, but they answer different questions. Report the 7.2 mg result with its estimand before comparing it with 2.4 mg or another trial. Otherwise adherence and intercurrent-event assumptions become hidden, making apparent differences look more biologically direct or clinically transportable than the analysis supports.

Sources: UP; HD.

8. What limits a structural explanation of clinical efficacy?

Established. PDB 7KI0 captures a semaglutide–GLP-1R–Gs complex, while PDB 5VAI uses GLP-1 and a different experimental structure. These entries help study receptor architecture but are not interchangeable ligand evidence. Detailed contact comparisons require construct, numbering and coordinate checks. A structural image cannot quantify human appetite, adverse effects or clinical-event reduction without functional and clinical evidence, so the page should keep those evidentiary layers visible rather than imply one image validates them all.

Sources: Structure; PDB entries in 02.

Chemist

Questions for this perspective

8 drafted questions in this packet. A perspective-specific question set.

1. Why can oral 25 mg produce exposure near injected 2.4 mg?

Established. The two routes deliver different fractions of the administered mass into circulation. The label estimates about 1–2% oral bioavailability and 89% subcutaneous bioavailability. Without T2D, mean concentrations are approximately 77 versus 75 nmol/L, but oral variability is wider. This is not a simple arithmetic conversion: absorption conditions and population matter, and T2D means differ. Use labeled transition guidance rather than infer interchangeability from molecular identity or one exposure average.

Sources: L §§2.5,8.6,12.3.

2. What are semaglutide’s principal design modifications?

Established. The design includes Aib at position 8 to improve DPP-4 resistance, a fatty-diacid attachment at Lys 26 that promotes albumin binding, and Arg at position 34 in place of the second lysine. These features address degradation and exposure while retaining GLP-1 receptor agonism. The exact spacer geometry and detailed structure-activity contributions should come from inspected chemistry figures, not a mnemonic that attributes the entire clinical half-life to one substitution.

Sources: Lau; L §§11,12.3.

3. What is the distinction between SNAC and the acyl side chain?

Established. SNAC is the tablet’s salcaprozate-sodium absorption enhancer, acting in the gastric delivery context. The fatty-diacid side chain is covalently attached to semaglutide and promotes albumin association after systemic uptake. They solve different problems and should be drawn separately. SNAC does not create a new receptor target, and albumin binding does not by itself explain oral absorption. Labeling these components clearly prevents a formulation diagram from becoming a false molecular structure.

Sources: SNAC; Lau; L §§11,12.3.

4. Which deposited structure is semaglutide-bound?

Established. PDB 7KI0 is the semaglutide–GLP-1 receptor–Gs complex with reported 2.5 Å resolution. PDB 5VAI is an earlier activated GLP-1 receptor/G-protein structure associated with GLP-1, at 4.1 Å. The latter is useful context but should not be labeled another semaglutide-bound structure. Verify construct differences and residue numbering before comparing contacts, and distinguish experimental resolution from the certainty of any proposed atom-level interaction in a simplified illustration.

Sources: Structure; PDB entries in 02.

5. What happens to the peptide and fatty chain during elimination?

Established. The label describes proteolytic cleavage of the peptide backbone and sequential beta-oxidation of the fatty-acid side chain as the main metabolic routes. Drug-related material is eliminated through urine and feces. That broad account does not identify a quantified clinically active metabolite, nor does it justify assigning clearance to one named CYP enzyme. Keep the chemistry explanation at the level supported by the label unless a specific metabolite study is inspected.

Sources: L §12.3.

6. Does strong albumin binding make the drug permanently attached?

Established. The label reports more than 99% plasma albumin binding and links it to reduced renal clearance and protection from degradation. That is a population binding description, not proof that each molecule remains attached indefinitely. An educational drawing should show association without suggesting a permanent covalent albumin conjugate. The approximately one-week half-life reflects the whole disposition profile and cannot be attributed quantitatively to a single structural feature from this summary alone.

Sources: L §12.3; Lau.

7. Can a chemical formula predict the clinical dose response?

Established. Semaglutide’s formula, C187H291N45O59, identifies molecular composition but does not specify delivered exposure, receptor signaling in tissues or a trial’s clinical response. Formulation, dose, administration conditions and patient population intervene between composition and outcome. STEP UP directly compared regimens under a defined protocol; its result comes from that trial, not the formula. Preserve this separation when translating a medicinal-chemistry explanation into claims about more weight loss or improved organ outcomes.

Sources: L §11; UP.

8. Which detailed chemistry claims remain to be verified?

Uncertain. The principal substitutions, peptide formula, broad albumin-binding strategy and metabolic routes are supported in the retained sources. Exact spacer stereochemistry, construct-specific residue contacts and the causal effect of each interaction require full figures, coordinates and assay context. Those details remain explicit checks in this draft. Do not fill them with an attractive molecular rendering or treat a plausible hydrogen bond as a measured explanation of clinical potency without verifying the actual structure.

Sources: Lau; Structure; [VERIFY: detailed chemistry and coordinate audit].

Investor / Diligence Analyst

Questions for this perspective

8 drafted questions in this packet. A perspective-specific question set.

1. What price information is defensible as of this draft?

Established. Novo’s February 2026 announcement describes a future $675 monthly list price from January 2027. The April HD launch release quoted $399 monthly self-pay with restrictions, while its introductory $199 terms ended in June. Those are dated statements, not verified current transactions. Keep list price, historical offers, net revenue and patient cost separate, and verify the current pack and eligibility before using a figure in forecasts or public access copy.

Sources: WAC; HD; [VERIFY: current terms and scope].

2. What is the relevant patent horizon?

Established. The Wegovy NDA 215256 product listing includes compound patent 8,129,343 with a listed December 5, 2031 expiry and later product/use patents extending further. The audit’s Ozempic-based latest-patent reference does not capture the Wegovy listing. None of these dates alone predicts lawful generic entry, patent validity or litigation outcomes. Diligence should review claim scope, applicable presentation, exclusivities and current legal status with qualified analysis before turning a listing into a commercial forecast.

Sources: OB; [VERIFY: current patent scope and legal status].

3. What does the Medicare Bridge figure mean?

Established. CMS describes a $50 copay for eligible beneficiaries in its GLP-1 Bridge demonstration from July 2026 through December 2027. The program operates outside the usual Part D benefit payment flow and has eligibility and authorization requirements. It is not a universal $50 price for every Medicare patient or an insurance-market net-price assumption. Check the current program and covered product details before estimating addressable demand, uptake or manufacturer revenue from the headline copay.

Sources: CMS; [VERIFY: current program scope].

4. Is DKK 82.347 billion Wegovy revenue?

Established. No. The 2025 annual report figure is worldwide obesity-care category revenue, not a verified Wegovy-only or US-only figure. Treating it as product revenue would overstate the precision of the input. A financial model needs the relevant product, geography, period, currency and gross-versus-net definitions. Use the category number only with that label, and obtain the current product-level breakdown before assigning market share or revenue growth specifically to Wegovy.

Sources: Sales; [VERIFY: product-level financial breakdown].

5. Can prescription milestones be treated as patient counts?

Established. The manufacturer’s June announcement described three million prescriptions since the tablet launch, with attribution and a stated period. Prescriptions are not necessarily unique patients, persistent users or independently audited incremental demand. Before using the milestone in a model, inspect the underlying data source, refill treatment and definition of new-to-class starts. The draft keeps the statement separate from a current volume forecast and does not infer conversion or retention rates from the headline alone.

Sources: Manufacturer release; [VERIFY: underlying volume definitions].

6. Does an indirect competitor comparison establish superiority?

Uncertain. An indirect comparison depends on population matching, estimands, endpoint definitions and modeling assumptions across separate trials. The audit describes ORION as Novo-sponsored and indirect; its full methods have not been verified here. Do not present its claimed advantage as randomized head-to-head superiority over orforglipron. Zepbound and Foundayo diligence should use current labels and appropriately comparable evidence, while separating sponsor statements from independently assessed comparative conclusions and commercial forecasts.

Sources: [VERIFY: ORION full methods and current comparator labels].

7. What is commercially distinctive about the evidence package?

Established. Wegovy has evidence across adult weight reduction, adolescent BMI, cardiovascular events and MASH histology, with formulation and indication limits. SELECT provides clinical-event evidence; ESSENCE’s interim histology supports accelerated approval with confirmatory benefit outstanding. That breadth creates distinct questions for positioning and access, but does not establish the strongest outcome file in a measured class ranking. A diligence assessment should specify which product, population and endpoint each claimed advantage actually refers to.

Sources: STEP1; TEENS; SELECT; ESSENCE; L §1.

8. Did all compounded semaglutide supply end when the shortage resolved?

Uncertain. A shortage determination and the end of specified enforcement-discretion periods do not establish that every legal compounding pathway or all market supply ceased. The audit’s blanket phrase is therefore unsuitable as a market fact. Review current FDA policy, applicable statutory conditions and product-specific circumstances before estimating competitive supply. The present draft does not offer a legal conclusion, endorse an unapproved product or use a dated enforcement milestone as proof of complete market exit.

Sources: FDA policy; [VERIFY: current legal and supply context].

General

Questions for this perspective

3 drafted questions in this packet. Targeted additions or replacements for the current guide.

1. Does Wegovy directly burn fat?

Established. Wegovy reduces calorie intake, with appetite effects playing an important role. It also changes pancreatic glucose signals and slows stomach emptying. Those actions do not make it a direct fat-dissolving treatment. A human study measured lower meal intake after 20 weeks. A separate body-composition study found loss of both fat and lean mass. These measurements answer different questions: a change on the scale alone cannot identify the tissue lost or show whether strength changed.

Sources: L §12.2; Appetite; DXA.

2. Why are there separate heart and liver claims?

Established. Weight trials track body weight, while cardiovascular trials count events such as heart attack or stroke. SELECT found fewer of those events with the shot in the group studied. ESSENCE measured changes in liver tissue samples. Those results supported accelerated approval for a specific liver condition. Long-term health benefits still need confirmation. Each claim has its own group and product limits. A shared receptor does not make these endpoints the same or prove every hoped-for benefit.

Sources: SELECT; ESSENCE; L §1.

3. What is surprising about the pill and shot comparison?

Established. Low absorption does not by itself make a pill a weaker treatment. The tablet uses a different amount and formulation to deliver the active drug. Without type 2 diabetes, the label reports similar average drug levels for the studied pill and shot, with more variation for the pill. The averages differ in the diabetes datasets. A useful comparison names that population and uses its evidence. Matching milligrams on the boxes would miss those distinctions.

Sources: L §§8.6,12.3.